Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

Inclusion Criteria: * Uveal melanoma with histologic or cytologic confirmation of metastatic disease. * One unidimensionally measurable lesion. If this is a cutaneous lesion it must be at least 10 mm by caliper measure. If it is a visceral or nodal or soft tissue lesion, it must be \>20 mm with conventional techniques or \>10 mm with spiral CT scan. Bone lesions are not considered measurable. * Must not have received any prior systemic chemotherapy, immunotherapy, vaccine or hepatic arterial chemotherapy for metastatic disease. * Adequate liver, renal, and bone marrow function. * Zubrod performance status of 0-2. * Sign an informed consent form. Exclusion Criteria: * Major surgery within 4 weeks of enrollment. * Advanced symptomatic central nervous system (CNS) involvement by melanoma and those on phenytoin or requiring steroids for brain metastases, spinal cord compression, or meningeal "carcinomatosis". * History of neurological disorders unrelated to chemotherapy (including familial neurological diseases and acquired demyelinating disorders). * Grade 2 or greater sensory, motor and/or autonomic neuropathy at screening from any cause. * Receiving treatment with drugs known to inhibit or induce hepatic drug metabolism by cytochrome P450-3A4 isoenzymes and/or P-glycoprotein within 1 week of study enrollment.